Diana K Thiara1, Chia Ying Liu2, Fabio Raman3, Sabrina Mangat1, Julia B Purdy4, Horacio A Duarte5, Nancyanne Schmidt1, Jamie Hur1, Christopher T Sibley6, David A Bluemke2, Colleen Hadigan1. 1. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases. 2. Radiology and Imaging Sciences, Clinical Center. 3. Radiology and Imaging Sciences, Clinical Center Medical Scientist Training Program, University of Alabama at Birmingham. 4. Critical Care Medicine Department, National Institutes of Health, Bethesda, Maryland. 5. Department of Pediatrics, Seattle Children's Hospital/University of Washington School of Medicine. 6. Oregon Health and Science University, Knight Cardiovascular Institute, Portland.
Abstract
BACKGROUND: Impaired cardiac function persists in the era of effective human immunodeficiency virus (HIV) therapy, although the etiology is unclear. We used magnetic resonance imaging (MRI) to measure intramyocardial lipid levels and fibrosis as possible contributors to HIV-associated myocardial dysfunction. METHODS: A cross-sectional study of 95 HIV-infected and 30 matched-healthy adults, without known cardiovascular disease (CVD) was completed. Intramyocardial lipid levels, myocardial fibrosis, and cardiac function (measured on the basis of strain) were quantified by MRI. RESULTS: Systolic function was significantly decreased in HIV-infected subjects as compared to controls (mean radial strain [±SD], 21.7 ± 8.6% vs 30.5 ± 14.2%; P = .004). Intramyocardial lipid level and fibrosis index were both increased in HIV-infected subjects as compared to controls (P ≤ .04 for both) and correlated with the degree of myocardial dysfunction measured by strain parameters. Intramyocardial lipid levels correlated positively with antiretroviral therapy duration and visceral adiposity. Further, impaired myocardial function was strongly correlated with increased monocyte chemoattractant protein 1 levels (r = 0.396, P = .0002) and lipopolysaccharide binding protein levels (r = 0.25, P = .02). CONCLUSIONS: HIV-infected adults have reduced myocardial function as compared to controls in the absence of known CVD. Decreased cardiac function was associated with abnormal myocardial tissue composition characterized by increased lipid levels and diffuse myocardial fibrosis. Metabolic alterations related to antiretroviral therapy and chronic inflammation may be important targets for optimizing long-term cardiovascular health in HIV-infected individuals. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Impaired cardiac function persists in the era of effective human immunodeficiency virus (HIV) therapy, although the etiology is unclear. We used magnetic resonance imaging (MRI) to measure intramyocardial lipid levels and fibrosis as possible contributors to HIV-associated myocardial dysfunction. METHODS: A cross-sectional study of 95 HIV-infected and 30 matched-healthy adults, without known cardiovascular disease (CVD) was completed. Intramyocardial lipid levels, myocardial fibrosis, and cardiac function (measured on the basis of strain) were quantified by MRI. RESULTS: Systolic function was significantly decreased in HIV-infected subjects as compared to controls (mean radial strain [±SD], 21.7 ± 8.6% vs 30.5 ± 14.2%; P = .004). Intramyocardial lipid level and fibrosis index were both increased in HIV-infected subjects as compared to controls (P ≤ .04 for both) and correlated with the degree of myocardial dysfunction measured by strain parameters. Intramyocardial lipid levels correlated positively with antiretroviral therapy duration and visceral adiposity. Further, impaired myocardial function was strongly correlated with increased monocyte chemoattractant protein 1 levels (r = 0.396, P = .0002) and lipopolysaccharide binding protein levels (r = 0.25, P = .02). CONCLUSIONS:HIV-infected adults have reduced myocardial function as compared to controls in the absence of known CVD. Decreased cardiac function was associated with abnormal myocardial tissue composition characterized by increased lipid levels and diffuse myocardial fibrosis. Metabolic alterations related to antiretroviral therapy and chronic inflammation may be important targets for optimizing long-term cardiovascular health in HIV-infected individuals. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: S B Yeon; N Reichek; B A Tallant; J A Lima; L P Calhoun; N R Clark; E A Hoffman; K K Ho; L Axel Journal: J Am Coll Cardiol Date: 2001-08 Impact factor: 24.094
Authors: Martin Ugander; Abiola J Oki; Li-Yueh Hsu; Peter Kellman; Andreas Greiser; Anthony H Aletras; Christopher T Sibley; Marcus Y Chen; W Patricia Bandettini; Andrew E Arai Journal: Eur Heart J Date: 2012-01-24 Impact factor: 29.983
Authors: Seng Khee Gan; Katherine Samaras; Campbell H Thompson; Edward W Kraegen; Andrew Carr; David A Cooper; Donald J Chisholm Journal: Diabetes Date: 2002-11 Impact factor: 9.461
Authors: B Gaborit; F Kober; A Jacquier; P J Moro; T Cuisset; S Boullu; F Dadoun; M-C Alessi; P Morange; K Clément; M Bernard; A Dutour Journal: Int J Obes (Lond) Date: 2011-07-05 Impact factor: 5.095
Authors: Marit Granér; Reijo Siren; Kristofer Nyman; Jesper Lundbom; Antti Hakkarainen; Markku O Pentikäinen; Kirsi Lauerma; Nina Lundbom; Martin Adiels; Markku S Nieminen; Marja-Riitta Taskinen Journal: J Clin Endocrinol Metab Date: 2013-02-15 Impact factor: 5.958
Authors: Michael D Nelson; Lidia S Szczepaniak; Troy M LaBounty; Edward Szczepaniak; Debiao Li; Mourad Tighiouart; Quanlin Li; Rohan Dharmakumar; Gregg Sannes; Zhaoyang Fan; Roya Yumul; W David Hardy; Antonio Hernandez Conte Journal: JACC Cardiovasc Imaging Date: 2014-11-10
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Kristin E Mondy; John Gottdiener; E Turner Overton; Keith Henry; Tim Bush; Lois Conley; John Hammer; Charles C Carpenter; Erna Kojic; Pragna Patel; John T Brooks Journal: Clin Infect Dis Date: 2010-12-09 Impact factor: 9.079
Authors: Robert D O'Connor; Jian Xu; Gregory A Ewald; Joseph J H Ackerman; Linda R Peterson; Robert J Gropler; Adil Bashir Journal: Magn Reson Med Date: 2011-01-10 Impact factor: 4.668
Authors: Markella V Zanni; Magid Awadalla; Mabel Toribio; Jake Robinson; Lauren A Stone; Diana Cagliero; Adam Rokicki; Connor P Mulligan; Jennifer E Ho; Anne M Neilan; Mark J Siedner; Virginia A Triant; Takara L Stanley; Lidia S Szczepaniak; Michael Jerosch-Herold; Michael D Nelson; Tricia H Burdo; Tomas G Neilan Journal: J Infect Dis Date: 2020-03-28 Impact factor: 5.226
Authors: Matthew J Feinstein; Milana Bogorodskaya; Gerald S Bloomfield; Rajesh Vedanthan; Mark J Siedner; Gene F Kwan; Christopher T Longenecker Journal: Curr Cardiol Rep Date: 2016-11 Impact factor: 2.931